Encellin, a biotechnology company pioneering Encapsulated Cell Replacement Therapy (ENCRT), today announced interim clinical results from its ongoing Phase 1 investigational trial (NCT06408311) in ...
Type 1 diabetes, or T1D, results from the autoimmune destruction of the insulin-producing cells of the pancreas. People with T1D require exogenous insulin and suffer swings in the levels of glucose in ...
The potential to treat type 1 diabetes using transplanted islet cells has long been recognized, but in reality this has proven challenging partly because the transplanted islet cells die if they don’t ...
Type 1 diabetes, or T1D, results from the autoimmune destruction of the insulin-producing cells of the pancreas. People with T1D require exogenous insulin and suffer swings in the levels of glucose in ...
NEW YORK, April 27, 2010 – The Juvenile Diabetes Research Foundation announced today that it is partnering with Living Cell Technologies (LCT), a New Zealand-based biotechnology company focused on ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The experimental encapsulated cell ...
Avant Technologies, Art-Islets, and Austrianova Announce Joint Venture to Advance Diabetes Treatment
LAS VEGAS, Sept. 24, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), a Nevada-based corporation, Art-Islets Pte. Ltd. ("Art ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced the achievement of pre-clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback